摘要
目的探讨坎地沙坦酯联合瑞舒伐他汀治疗慢性心力衰竭并阵发性心房纤颤的效果。方法慢性心力衰竭并阵发性心房纤颤病人92例,随机分为坎地沙坦酯组49例,坎地沙坦酯并瑞舒伐他汀组（联合用药组）43例,共用药12个月,分别于用药前后测定两组病人12导联体表心电图中P波最大时限、P波离散度及血清C反应蛋白（CRP）水平,比较两组心房纤颤的发生率。结果用药后两组病人心电图P波最大时限均缩短（t=7.75、10.64,P〈0.01）、P波离散度减小（t=2.87、5.81,P〈0.01）、CRP水平降低（t=3.30、6.80,P均〈0.01）;且联合用药组治疗后对P波最大时限、P波离散度、CRP水平的影响程度比单用坎地沙坦酯组显著（t=3.07～4.76,P〈0.01）。联合用药组治疗后心房纤颤发生率低于坎地沙坦酯组（χ^2=5.01,P〈0.05）。结论坎地沙坦酯联合瑞舒伐他汀可有效治疗慢性心力衰竭并阵发性心房纤颤,可更好地维持窦性节律,以预防心房纤颤的复发。
Objective To investigate the effects of cotherapy with candesartan cilexetil and rosuvastatin on patients with chronic cardiac insufficiency（CCI）and paroxysmal atrial fibrillation（PAF）. Methods Ninety-two patients with CCI and PAF were dived into candesartan cilexetil group（n=49）and combination group（candesartan cilexetil plus rosuvastatin,n=43）in random.A follow-up of 12 months was conducted.Before and after medication,the maximum P-wave duration and P-dispersion were measured,and serum C reactive protein（CRP）levels detected.The incidence of PAF was compared between the two groups. Results After medication,the maximum P-wave duration was shortened（t=7.75,10.64;P〈0.01）,and P-dispersion decreased（t=7.75,10.64;P〈0.01）,and serum CRP levels declined（t=3.30,6.80;P〈0.01）in the two groups.A comparison between the two groups indicated that the effects of combined medication on the maximum P-wave duration,P-dispersion,and serum CRP levels were more significant than that in the candesartan cilexetil group（t=3.07-4.76,P〈0.01）,the incidence of atrial fibrillation was lower（χ^2=5.01,P〈0.05）. Conclusion A combination use of candesartan cilexetil with rosuvastatin can effectively treat patients with chronic cardiac insufficiency and paroxysmal atrial fibrillation,can better maintain sinus rhythm,and prevent recurrence of atrial fibrillation.
出处
《齐鲁医学杂志》
2015年第5期587-589,共3页
Medical Journal of Qilu
关键词
心力衰竭
心房纤颤
坎地沙坦酯
瑞舒伐他汀
治疗结果
heart failure
atrial fibrillation
candesartan cilexetil
rosuvastatin
treatment outcome
